As the world’s third-largest pharmaceutical market, Japan features a sophisticated regulatory framework, a premium reimbursement environment, and a strong openness to innovative drugs, making it a strategic hub for Chinese innovative drugs going global. How can companies leverage Japan as a pivot to expand their global footprint?

The full agenda for the China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies is officially released today.This session will gather policy experts, clinical researchers, corporate strategists, and investment institutions from both the Chinese and Japanese pharmaceutical industries. Participants will conduct in-depth discussions on new drug market trends in Japan, strategic pathways for Chinese innovative drugs entering the Japanese market, practical clinical R&D operations, and actionable implementation models for Sino-Japanese industrial collaboration. It aims to systematically analyze the new global expansion paradigm of "driving global development via Japan."

We look forward to exploring the pathways to Japan for Chinese innovative drugs with you at the National Exhibition and Convention Center (Shanghai) from July 22 to 24.

Agenda

Session Time: Morning of July 24

Moderator

Keiji Kawamoto：Kawamoto BioBusiness Partners，Representative           
RuiPing Dong：RealOne Medicines, founder and Chairman

09:00-09:25　Latest Trends and Innovation Environment in Japan’s New Drug Market

Yuji Kato：Editor-in-Chief，Nikkei(日経) Biotechnology & Business

09:25-09:50　Strategies, Collaborative Scenarios, and Key Success Factors for Initiating Clinical Trials for Chinese Innovative Drugs Entering Japan
Fugen Li：SVP, Haihe Biopharma

09:50-10:15　Practical Guidance for Initiating Clinical R&D of Chinese Innovative Drugs in Japan

Rokuya NOCHI：Executive Officer, Global Business Promotion，EPS Corporation 

10:15-10:40　MNC Reverse Roadshow

Issei Tsukamoto：senior vice president and global Head of Business Development(BD)，Astellas

10:40-11:05　Collaborative Synergy with Japanese R&D Institutions and Biopharma Enterprises
Hiroki Narita ：Chief Executive Officer，Daiwa(大和) Corporate Investment(DCI)

11:05-12:00　Panel Discussion：Global Footprint Strategy for Chinese Innovative Drugs: How to Leverage Japan’s Market to Boost Overseas Expansion

Dong Ruiping (Moderator)：RealOne Medicines, founder and Chairman

Panelists (Japan Side)
Issei Tsukamoto ：senior vice president and global Head of Business Development(BD)，Astellas

Tetsuya Hagiwara, Ph.D.：Vice President, Head of Business Development, Japan Kyowa Kirin, Co., Ltd.
Masatora Shirasawa：Manager of Overseas Development Department, Head of Greater China, TOHO HOLDINGS Co., Ltd.

Panelists (China Side)：
Anbo Xiang：Chief Medical Officer of Non-Oncology, CSPC Pharmaceutical Group

Li Fugen: SVP of Haihe Biopharma
Tigermed